Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 4, 2009

Grant to Pluristem Increased by $0.4M to Advance Cell Therapy for Critical Limb Ischemia

  • The Israeli government’s Office of the Chief Scientist has increased a grant awarded in June to local company Pluristem from $1.9 million to $2.3 million. The funds will be used primarily to support clinical trials of Pluristem’s allogeneic placental-derived adherent stromal cell product, PLX-PAD, for the treatment of critical limb ischemia. A Phase I trial was initiated in July.

    Pluristem is focused on developing allogeneic cell therapy products for severe degenerative, ischemic, and autoimmune disorders. It uses human placenta as a source of nonembryonic, adult stem cells. The technology involves expanding placental adherent stromal cells in the company's PluriXTM 3-D bioreactor system.

    Pluristem says that this bioreactor provides a 3-D microenvironment that enables large-scale growth of cells without the need for supplemental growth factors or other exogenous materials. Resulting placental expanded cell products are designed to be off-the-shelf, ready-to-use, and require no histocompatibility matching, the firm explains. In February Pluristem’s European facilities were cleared for cGMP manufacturing of its cell therapy products.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »